Projected estimates of cancer in Canada in 2020
- PMID: 32122974
- PMCID: PMC7055947
- DOI: 10.1503/cmaj.191292
Projected estimates of cancer in Canada in 2020
Abstract
Background: Cancer projections to the current year help in policy development, planning of programs and allocation of resources. We sought to provide an overview of the expected incidence and mortality of cancer in Canada in 2020 in follow-up to the Canadian Cancer Statistics 2019 report.
Methods: We obtained incidence data from the National Cancer Incidence Reporting System (1984-1991) and Canadian Cancer Registry (1992-2015). Mortality data (1984-2015) were obtained from the Canadian Vital Statistics - Death Database. All databases are maintained by Statistics Canada. Cancer incidence and mortality counts and age-standardized rates were projected to 2020 for 23 cancer types by sex and geographic region (provinces and territories) for all ages combined.
Results: An estimated 225 800 new cancer cases and 83 300 cancer deaths are expected in Canada in 2020. The most commonly diagnosed cancers are expected to be lung overall (29 800), breast in females (27 400) and prostate in males (23 300). Lung cancer is also expected to be the leading cause of cancer death, accounting for 25.5% of all cancer deaths, followed by colorectal (11.6%), pancreatic (6.4%) and breast (6.1%) cancers. Incidence and mortality rates will be generally higher in the eastern provinces than in the western provinces.
Interpretation: The number of cancer cases and deaths remains high in Canada and, owing to the growing and aging population, is expected to continue to increase. Although progress has been made in reducing deaths for most major cancers (breast, prostate and lung), there has been limited progress for pancreatic cancer, which is expected to be the third leading cause of cancer death in Canada in 2020. Additional efforts to improve uptake of existing programs, as well as to advance research, prevention, screening and treatment, are needed to address the cancer burden in Canada.
© 2020 Joule Inc. or its licensors.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Projected estimates of cancer in Canada in 2022.CMAJ. 2022 May 2;194(17):E601-E607. doi: 10.1503/cmaj.212097. CMAJ. 2022. PMID: 35500919 Free PMC article.
-
Projected estimates of cancer in Canada in 2024.CMAJ. 2024 May 12;196(18):E615-E623. doi: 10.1503/cmaj.240095. CMAJ. 2024. PMID: 38740416 Free PMC article.
-
1992 Canadian Cancer Statistics.Health Rep. 1992;4(2):161-74. Health Rep. 1992. PMID: 1421019 English, French.
-
Cancer incidence in Canada: trends and projections (1983-2032).Health Promot Chronic Dis Prev Can. 2015 Spring;35 Suppl 1:2-186. Health Promot Chronic Dis Prev Can. 2015. PMID: 26011811 Review. English, French.
-
Cancer statistics, 2004.CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8. CA Cancer J Clin. 2004. PMID: 14974761 Review.
Cited by
-
The Impact of BRAF Mutation Status on Survival Outcomes and Treatment Patterns among Metastatic Colorectal Cancer Patients in Alberta, Canada.Cancers (Basel). 2023 Dec 8;15(24):5748. doi: 10.3390/cancers15245748. Cancers (Basel). 2023. PMID: 38136294 Free PMC article.
-
Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?Curr Oncol. 2021 Apr 21;28(3):1558-1570. doi: 10.3390/curroncol28030147. Curr Oncol. 2021. PMID: 33919428 Free PMC article. Review.
-
Exploring the Future of Cancer Impact in Alberta: Projections and Trends 2020-2040.Curr Oncol. 2023 Nov 18;30(11):9981-9995. doi: 10.3390/curroncol30110725. Curr Oncol. 2023. PMID: 37999145 Free PMC article.
-
Conservative interventions and clinical outcome measures used in the perioperative rehabilitation of breast cancer patients undergoing mastectomy: a scoping review.BMC Womens Health. 2022 Aug 16;22(1):343. doi: 10.1186/s12905-022-01927-3. BMC Womens Health. 2022. PMID: 35974334 Free PMC article. Review.
-
Arsenic Speciation and Metallomics Profiling of Human Toenails as a Biomarker to Assess Prostate Cancer Cases: Atlantic PATH Cohort Study.Front Public Health. 2022 Jul 7;10:818069. doi: 10.3389/fpubh.2022.818069. eCollection 2022. Front Public Health. 2022. PMID: 35875010 Free PMC article.
References
-
- Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics 2019. Toronto: Canadian Cancer Society; 2019. Available: www.cancer.ca/~/media/cancer.ca/CW/publications/Canadian%20Cancer%20Stat... (accessed 2020 Jan. 17).
-
- Table 13-10-0394-01: Leading causes of death, total population, by age group. Ottawa: Statistics Canada; Available: www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401 (accessed 2020 Jan. 17).
-
- Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer statistics 2015. Toronto: Canadian Cancer Society; 2015. Available: www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Can... (accessed 2020 Jan. 17).
-
- Xie L, Semenciw R, Mery L. Cancer incidence in Canada: trends and projections (1983–2032). Health Promot Chronic Dis Prev Can 2015;35(Suppl 1):2–186. - PubMed
-
- Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–21. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources